11 research outputs found
Levovist in the breast nodular lesions = Le levovist dans les lesions nodulaires du sein
Our aim was to evaluate the effectiveness of Levovist SHU 508 A (Shering, Germany) in the characterization of breast lesions. From June 1996 to May 1997 we studied 29 solid lesions in 29 patients (28 women and one man) between the age of 17 and 83 years. The 29 solid lesions included of 20 carcinomas (15 DCI ductal invasive carcinoma, 4 DCIS ductal carcinoma in situ, 1 LCIS lobular carcinoma in situ) 6 fibroadenomas, 1 postsurgical lesion and 2 apparently benign lesions at mammography, suspected after contrast agent injection, with histologically proven malignancy. We used parameters suitable for the study of low flow. A single bolus of contrast, at a concentration of 300 mg/ml, was administrated at a rate of 1-2 ml/sec. Morphological parameters, considered, before the administration of the Levovist were signal intensity and number of vascular poles. After contrast we assessed the previous parameters and the following: the presence and modification of vessels, not seen at the previous ultrasound exam, the increased in the number of vessels the initial modification, the duration of enhancement, and the presence of vessels within and external to the lesion. Considering the signal intensity after contrast there was no improvement in 17 % of cases, mild increases in 7 % and marked improvement in 76 % of cases. We have obtained an increase in the number of vessels in 10 % of cases. The type of enhancement characteristic of carcinoma (rapid increase, marked intensity) and fibroadenoma (slow increase with a lower intensity) were observed. This study demonstrated that Levovist can be useful in the following cases: differential diagnosis of benign from malignant lesions, differentiation between recurrence and post-surgical fibrosis, staging and follow-up of patients treated with chemotherapy
Shear wave elastography and microvascular ultrasound in response evaluation to calcipotriol+betamethasone foam in plaque psoriasis
Psoriasis (PsO) is a chronic skin disease. This study aims to evaluate clinical and subclinical response to calcipotriol+betamethasone foam, in patients with PsO, comparing, for the first time, data from microvascular ultrasound (MicroV) and shear wave elastography (SWE) with Psoriasis Area and Severity Index (PASI).Methods Between November 2018 and April 2019 in Tor Vergata Hospital (Roma, Italy), we enrolled 26 patients with PsO who were ageds 20-75 years, with PASI score >= 4, candidated for calcipotriol+betamethasone foam treatment. They underwent MicroV and SWE evaluation at baseline (T-0) and after 4 weeks of treatment (T-4). Clinical follow-up was carried on at T-4, T-8 and T-12. Student's t-test (p values<0.05 statistically significant) was used to compare SWE and PASI values.Results At T-0, SWE stiffness values of target plaques (61.5% on elbows, 23% knees, 7.7% sacrum,7.7% legs) were significantly higher than values under healthy skin. At T-4, all patients showed a significant reduction of PASI; MicroV showed reduction in vascularisation of responsive plaques in 85% of cases, only in 15%, the vascularisation degree remained stable; and SWE values of target plaques were significantly lower compared with T-0. Only in 7.7%, there was a relapse at T-12.Conclusions Calcipotriol+betamethasone foam is a very effective topical treatment in a short-medium term follow-up in patients with PsO. MicroV and SWE evaluate response to treatment (in term of plaque vascularisation and stiffness), so they could represent promising early indicators of therapeutic response and help the physician to establish a better clinical-therapeutic management of patients with PsO
Embolization of the uterine artery in the treatment of uterine myoma
STUDY OBJECTIVE: To evaluate the prevalence of different anatomic factors in
women with recurrent spontaneous abortion (RSA).
DESIGN: Retrospective analysis over 9 years (Canadian Task Force classification
II-2).
SETTING: University hospital-affiliated endoscopic unit.
PATIENTS: Three hundred forty-four consecutive patients with RSA and 922 controls
referred for abnormal uterine bleeding.
INTERVENTION: Diagnostic hysteroscopy.
MEASUREMENTS AND MAIN RESULTS: Major and minor uterine mullerian abnormalities
(septate, unicornuate uteri) were found significantly more often in women with
RSA than in controls (32% vs 6%, p <0.001). The frequency of acquired uterine
anomalies (submucous myomas, polyps) was significantly higher in controls (32% vs
9%, p <0.001). No significant differences were observed between groups in
frequency of adhesions (4% vs 2%).
CONCLUSION: Major mullerian uterine abnormalities are associated with RSA, and
minor uterine anomalies may be correlated with an increased risk of recurrent
miscarriage.
PMID: 11509781 [PubMed - indexed for MEDLINE]
46. Radiol Med. 2001 Mar;101(3):157-64.
[Embolization of the uterine artery in the treatment of uterine myoma].
[Article in Italian]
Simonetti G, Romanini C, Pocek M, Piccione E, Guazzaroni M, Zupi E, Gandini R,
Gabriele A, Vaquero E.
Istituto di Radiologia-Tor Vergata, Universitàdegli Studi Tor Vergata, Roma.
PURPOSE: To propose uterine myoma embolization as an alternative to myomectomy or
hysterectomy in the treatment of symptomatic myomas; to evaluate the efficacy of
the procedure in terms of clinical outcome, adopting all procedural and technical
precautions to ensure minimal X-ray exposure and preserve reproductive potential.
MATERIAL AND METHODS: Between April 1998 and February 2000, 26 patients, age
range 32-54 years (mean 41 years), underwent uterine arterial embolization for
menorrhagia, pelvic pain, and sensation of mass and pressure. Inclusion criteria
were: single myomas, intramural localization and rich vascolarization of the
lesion. Dose to patient was obtained by placing a thermoluminescent dosimeter
(Harshaw, Solon, Ohio) both placed in posterior fornix of the vagina and on the
skin at the beam entrance site. The procedure was performed under peridural
anesthesia; polyvinil alcohol particles 355-500 mu (Contour) (Target
Therapeutics, Boston Scientific Corporation, Fremont CA, USA) were employed as
embolic agent. The uterine arteries were incannulated with a 5F (Glidecath,
Terumo, Europe NV, Belgium) and successively 3F coaxial microcatheter (Target,
Boston Scientific Corporation, Fremont CA, USA); the embolic material was
injected as distally as possible. Color Power Doppler Ultrasound follow-up before
and after i.v. contrast media administration (Levovist SHU 508 A, Shering,
Berlin, Germany) was carried out at 15 days, at 1, at 3, at 6 months, and at 1
year from embolization. Pre-procedural evaluation and follow-up at 1 year was
performed by MRI using T1 and T2 weighted images before and after Gadolinium
(GdDTPA Shering, Berlin, Germany) administration.
RESULTS: The technical success of the interventional procedure was 100% (26/26
cases). The mean fluoroscopy time was 20 minutes, and the mean number of
angiographic exposures was 10. The mean estimated ovarian dose was 18.75 cGy and
the mean adsorbed skin dose was 126.71 cGy. The imaging follow-up showed a 55%
reduction of myoma volume at 6 months and a 75% reduction at 1 year. All patients
reported a marked decrease in symptoms. No major complications were observed. The
appearance of pelvic pain in the 24-48 hours after the procedure required
sedation by analgesic pump; transitorial amenorrhea was observed in 3 patients.
As for term complications, 2 patients have eliminated necrotic material through
the vagina four weeks after procedure. The patients reported great satisfaction
with the procedure.
DISCUSSION: Many treatment options are currently available for symptomatic
uterine myomas. One is surgical myomectomy which is associated with increased
blood loss, pain and post operative morbidity and requires an additional surgical
procedure for fibroma recurrence in 20-25% of patients. Another alternative
treatment is hormonal therapy, which drammatically improves symptoms and reduces
fibroid size although leiomyomas regrow to their original size within a few
months of discontinuing treatment. Uterine embolization is a relatively new
treatment for uterine fibroids that can be considered as an alternative to
surgical and medical procedures. The radiation exposure adsorbed by the patient
is reduced by using pulsed fluoroscopy and taking all the precautionary measures
required to minimize the dose.
CONCLUSIONS: The technical success, the patient' satisfation, the short
hospitalization time and preservation of fertility confer to uterine artery
embolization the role of a new alternative therapy for the treatment of
symptomatic uterine myoma
Embolization of the uterine artery in the treatment of uterine myoma [Embolizzazione delle arterie uterine nel trattamento dei miomi dell'utero.]
PURPOSE: To propose uterine myoma embolization as an alternative to myomectomy or hysterectomy in the treatment of symptomatic myomas; to evaluate the efficacy of the procedure in terms of clinical outcome, adopting all procedural and technical precautions to ensure minimal X-ray exposure and preserve reproductive potential. MATERIAL AND METHODS: Between April 1998 and February 2000, 26 patients, age range 32-54 years (mean 41 years), underwent uterine arterial embolization for menorrhagia, pelvic pain, and sensation of mass and pressure. Inclusion criteria were: single myomas, intramural localization and rich vascolarization of the lesion. Dose to patient was obtained by placing a thermoluminescent dosimeter (Harshaw, Solon, Ohio) both placed in posterior fornix of the vagina and on the skin at the beam entrance site. The procedure was performed under peridural anesthesia; polyvinil alcohol particles 355-500 mu (Contour) (Target Therapeutics, Boston Scientific Corporation, Fremont CA, USA) were employed as embolic agent. The uterine arteries were incannulated with a 5F (Glidecath, Terumo, Europe NV, Belgium) and successively 3F coaxial microcatheter (Target, Boston Scientific Corporation, Fremont CA, USA); the embolic material was injected as distally as possible. Color Power Doppler Ultrasound follow-up before and after i.v. contrast media administration (Levovist SHU 508 A, Shering, Berlin, Germany) was carried out at 15 days, at 1, at 3, at 6 months, and at 1 year from embolization. Pre-procedural evaluation and follow-up at 1 year was performed by MRI using T1 and T2 weighted images before and after Gadolinium (GdDTPA Shering, Berlin, Germany) administration. RESULTS: The technical success of the interventional procedure was 100% (26/26 cases). The mean fluoroscopy time was 20 minutes, and the mean number of angiographic exposures was 10. The mean estimated ovarian dose was 18.75 cGy and the mean adsorbed skin dose was 126.71 cGy. The imaging follow-up showed a 55% reduction of myoma volume at 6 months and a 75% reduction at 1 year. All patients reported a marked decrease in symptoms. No major complications were observed. The appearance of pelvic pain in the 24-48 hours after the procedure required sedation by analgesic pump; transitorial amenorrhea was observed in 3 patients. As for term complications, 2 patients have eliminated necrotic material through the vagina four weeks after procedure. The patients reported great satisfaction with the procedure. DISCUSSION: Many treatment options are currently available for symptomatic uterine myomas. One is surgical myomectomy which is associated with increased blood loss, pain and post operative morbidity and requires an additional surgical procedure for fibroma recurrence in 20-25% of patients. Another alternative treatment is hormonal therapy, which drammatically improves symptoms and reduces fibroid size although leiomyomas regrow to their original size within a few months of discontinuing treatment. Uterine embolization is a relatively new treatment for uterine fibroids that can be considered as an alternative to surgical and medical procedures. The radiation exposure adsorbed by the patient is reduced by using pulsed fluoroscopy and taking all the precautionary measures required to minimize the dose. CONCLUSIONS: The technical success, the patient' satisfation, the short hospitalization time and preservation of fertility confer to uterine artery embolization the role of a new alternative therapy for the treatment of symptomatic uterine myomas
Evaluation of a cardiac sarcoma with CT multislice contrast-enhanced and 18FDG-PET/TC
We present the case of an adult male who arrived to our emergency room with progressive dyspnea that had been ongoing for 2 months. During the radiological investigation, we found a large intracardiac mass, which invaded the pericardium, pulmonary trunk, pulmonary arteries, and left ventricle. Studies done with the 18FDG-PET/CT scan helped us to determine the malignant nature of the mass and to suspect the diagnosis of rhabdomyosarcoma. Keywords: Cardiac Sarcoma, Computed Tomography, PET/C
PET–CT in oncological patients: analysis of informal care costs in cost–benefit assessment
PURPOSE:
The authors analysed the impact of nonmedical costs (travel, loss of productivity) in an economic analysis of PET-CT (positron-emission tomography-computed tomography) performed with standard contrast-enhanced CT protocols (CECT).
MATERIALS AND METHODS:
From October to November 2009, a total of 100 patients referred to our institute were administered a questionnaire to evaluate the nonmedical costs of PET-CT. In addition, the medical costs (equipment maintenance and depreciation, consumables and staff) related to PET-CT performed with CECT and PET-CT with low-dose nonenhanced CT and separate CECT were also estimated.
RESULTS:
The medical costs were 919.3 euro for PET-CT with separate CECT, and 801.3 euro for PET-CT with CECT. Therefore, savings of approximately 13% are possible. Moreover, savings in nonmedical costs can be achieved by reducing the number of hospital visits required by patients undergoing diagnostic imaging.
CONCLUSIONS:
Nonmedical costs heavily affect patients' finances as well as having an indirect impact on national health expenditure. Our results show that PET-CT performed with standard dose CECT in a single session provides benefits in terms of both medical and nonmedical costs